目的 研究福辛普利联合羟苯磺酸钙治疗长期腹膜透析糖尿病肾病患者的临床疗效和安全性。方法 将67例长期进行腹膜透析的糖尿病肾病患者随机分为对照组（36例）和治疗组（31例），对照组口服福辛普利钠片，10 mg/次，3次/d。治疗组口服羟苯磺酸钙分散片，0.5 g/次，3次/d，福辛普利的用法和用量同对照组。两组患者均治疗12周。治疗后，比较两组的临床疗效、肾功能改善情况、血糖控制情况。结果 治疗后治疗组和对照组的临床总有效率分别为87.1%、63.9%，两组比较差异有统计学意义（P＜0.05）。治疗后，治疗组肾功能改善更好，患者尿素氮、血清肌酐，24 h尿蛋白量下降程度较对照组更明显，差异有统计学意义（P＜0.05）。治疗后，治疗组糖化血红蛋白、空腹血糖和餐后2 h血糖均较对照组下降更加明显，两组比较差异有统计学意义（P＜0.05）。结论 福辛普利联合羟苯磺酸钙治疗长期腹膜透析糖尿病肾病患者临床疗效较好，对患者肾功能的恢复有一定作用，值得临床推广。

Objective To investigate the clinical efficacy and safety of fosinopril combined with calcium dobesilate in treatment of long-term peritoneal dialysis patients with diabetic nephropathy. Methods Sixty-seven cases of long-term peritoneal dialysis patients with diabetic nephropathy were randomly divided into treatment (31 cases) and control (36 cases) groups. The patients in the control group were po administered with fosinopril 10 mg once, three times daily. The patients in the treatment group were po administered with calcium dobesilate 0.5 g once, three times daily. At the same time, fosinopril at the usage and dosage was used as same in the control group. Two groups were treated for 12 weeks. After the treatment, the clinical curative effects on improving renal function and controlling blood sugar in the two groups were compared. Results After the treatment, the total effective rates in the treatment and control groups were 87.1% and 63.9%. And there were significant differences between the two groups (P<0.05). After the treatment, the improvement of renal function in the treatment group was better. The urea nitrogen, serum creatinine, and decreased degree of 24 h urine protein were more significant than those in the control group, and the difference between the two groups was statistically significant (P<0.05). After the treatment, glycosylated hemoglobin, fasting blood glucose, and blood glucose in postprandial 2 h in the treatment group were down more obviously compared with the control group, the difference was statistically significant (P<0.05). Conclusion Fosinopril combined with calcium dobesilate has a good antihypertensive effect in the treatment of long-term peritoneal dialysis patients with diabetic nephropathy, and it has the certain effect for recovery of renal function, which is worth clinical promotion.